Abstract Oncolytic viruses (OV) are thought to mediate antitumor activity by killing tumor cells and inducing antitumor immunity, but how this happens is not well understood. In this issue, Ludwig and colleagues show that PVSRIPO, an oncolytic poliovirus being developed for glioblastoma, may induce better immune and therapeutic responses when injected into both tumor and tumor-draining lymph nodes. Dual delivery may be a novel approach to optimize OV treatment and has implications for how we manage patients with solid tumors in the era of local immunotherapy. See related article by Ludwig et al., p. XX
Howard L. Kaufman (Wed,) studied this question.